Biodesix (NASDAQ:BDSX) Director Acquires $236,000.00 in Stock

Biodesix, Inc. (NASDAQ:BDSX) Director Jack Schuler bought 20,000 shares of the firm’s stock in a transaction that occurred on Monday, January 26th. The shares were acquired at an average price of $11.80 per share, with a total value of $236,000.00. Following the acquisition, the director owned 1,563,210 shares of the company’s stock, valued at $18,445,878. This represents a 1.30% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Biodesix Stock Up 10.2%

Biodesix stock traded up $1.03 on Tuesday, hitting $11.12. 67,524 shares of the stock traded hands, compared to its average volume of 4,904,886. Biodesix, Inc. has a 1 year low of $3.44 and a 1 year high of $21.60. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of 41.11. The business’s fifty day simple moving average is $7.67 and its 200 day simple moving average is $7.69. The firm has a market cap of $88.48 million, a P/E ratio of -2.00 and a beta of 0.60.

Biodesix (NASDAQ:BDSX) last released its earnings results on Monday, November 3rd. The company reported ($1.16) EPS for the quarter, topping analysts’ consensus estimates of ($1.60) by $0.44. The firm had revenue of $21.77 million for the quarter, compared to analysts’ expectations of $20.98 million. Biodesix had a negative return on equity of 504.41% and a negative net margin of 49.31%. As a group, sell-side analysts forecast that Biodesix, Inc. will post -0.35 earnings per share for the current year.

Hedge Funds Weigh In On Biodesix

Several institutional investors and hedge funds have recently bought and sold shares of BDSX. XTX Topco Ltd increased its holdings in shares of Biodesix by 99.4% in the 2nd quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock valued at $58,000 after acquiring an additional 102,494 shares during the period. Millennium Management LLC acquired a new position in Biodesix during the 3rd quarter worth approximately $113,000. Oracle Investment Management Inc. acquired a new position in Biodesix during the third quarter worth $113,000. Finally, Aberdeen Group plc purchased a new position in shares of Biodesix in the 4th quarter valued at about $1,784,000. 20.96% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on BDSX. Weiss Ratings reiterated a “sell (e+)” rating on shares of Biodesix in a research report on Monday, December 22nd. Wall Street Zen upgraded Biodesix from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Biodesix currently has a consensus rating of “Moderate Buy” and a consensus price target of $32.50.

About Biodesix

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.